Ebenbuild logo — Personalized health intelligence for the lung

Ebenbuild

Personalized health intelligence for the lung

Founded 2019 Germany Munchen, Germany 31 employees Unknown Total: $5.73M Health Care, Medical Devices

General Information

Company Name Ebenbuild
Founded Year 2019
Location Germany Munchen, Germany +1
Employees 31
Industries Health Care, Medical Devices
Funding Stage Unknown
Social

Get notified when Ebenbuild moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Ebenbuild

Ebenbuild is a digital health tech pioneer striving to revolutionize the field with its slogan, "Precision therapy based on personalized digital twins." Founded in 2019 and headquartered in Germany, Ebenbuild is focused on developing precise, patient-specific simulation models of lungs, known as digital twins of the lungs. Through a digital toolset that integrates physics-based simulation, AI, and data science, the company aims to provide crucial support to decision-makers in the life sciences industry, clinicians, and physicians. Ebenbuild's innovative approach offers a deeper understanding of respiratory diseases and individual pathophysiology, leading to a new class of products and services. These range from in silico trials that can accelerate and de-risk the development of inhaled drugs to personalized treatment options that enhance the chances of survival and recovery for millions of individuals affected by respiratory conditions such as Acute Respiratory Distress Syndrome (ARDS) each year. The company recently secured a Seed Round investment on 31 March 2022, with backing from High-Tech Gründerfonds and Bayern Kapital. This support signals confidence in Ebenbuild's potential to drive significant advancements in the healthcare industry through its cutting-edge approach.

Taxonomy: digital health tech, precision therapy, personalized medicine, respiratory diseases, lung simulation models, AI in healthcare, data science in healthcare, in silico trials, drug delivery optimization, clinical decision support, mechanical ventilation personalization, healthcare IT integration, deep tech

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Support Program •••••• 1
Investor
01 Mar 2025
Grant •••••• - 01 Nov 2023
Seed •••••• 2
Investor Investor
01 Apr 2022
Support Program •••••• 1 •••• •••• 01 Jan 2021
Spinout •••••• 1 •••• •••• 01 Apr 2019

Ebenbuild Alternatives & Competitors

Ebenbuild vs
Misti
Misti Australia

Next-generation lung delivery to protect every vulnerable child and adult from infections

Pre Seed
12 employees
Biotechnology, Health Care
Ebenbuild vs
Onescope
Onescope Switzerland

A revolutionary AI-powered medical device decentralizing the diagnosis and management of respiratory...

Grant
3 employees
Manufacturing
Ebenbuild vs
CAE Healthcare
CAE Healthcare United States

Preparing You for the Moments that Matter

476 employees
Health Care

FAQ About Ebenbuild

Personalized health intelligence for the lung
Ebenbuild was founded in 2019.
Ebenbuild is headquartered in Munchen, Germany.
Ebenbuild operates in the following industries: Health Care, Medical Devices.
Ebenbuild has approximately 31 employees.
Ebenbuild has completed 5 funding rounds, raising a total of $5.73M. The latest funding stage is Unknown.
Top alternatives and competitors to Ebenbuild include Misti, Onescope, CAE Healthcare, Propeller Health, Enterprise Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Ebenbuild and Misti are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Ebenbuild and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes